It’s good to understand how things work, but in medicine, it’s more important to know that they do work. Our research is focused on developing novel Presponse™ therapeutics so physicians will know if their patient is likely to benefit before they commit to treatment. We know that getting the right treatment to the right patient the first time is critical to success in the fight against cancer.
Responder-Focused Therapeutics
By combining existing, de-risked drugs with a proprietary predicted responder diagnostic, we are working to create novel Presponse™ therapeutics. Through our research, we are committed to dramatically increasing the clinical response rates of our therapeutics while reducing the risk, time and cost of development. We seek to identify and treat only those patients who are most likely to benefit. The initial focus of our research is on predicted responders with relapsed/refractory acute myeloid leukemia (R/R AML).
